Standard BioTools Inc. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
Standard BioTools Inc. (LAB) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $2.69 million as of 2025-03-31, per its 10-Q filed 2025-05-06.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2025-05-06
- 2025-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $2.69M.
- 2024-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $711.00K.
- 2024-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.42M.
- 2024-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $2.16M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2025-03-31 | $2.69M 10-Q · filed 2025-05-06 |
| 2024-09-30 | $711.00K 10-Q · filed 2024-11-06 |
| 2024-06-30 | $1.42M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $2.16M 10-Q · filed 2024-05-09 |
| 2023-09-30 | $2.87M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $5.83M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $8.80M 10-Q · filed 2023-05-09 |
| 2022-09-30 | $2.97M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $5.94M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $9.41M 10-Q · filed 2022-05-09 |
| 2021-09-30 | $3.15M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $6.30M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $9.46M 10-Q · filed 2021-05-07 |
| 2020-09-30 | $3.21M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $6.39M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $9.59M 10-Q · filed 2020-05-11 |
| 2019-09-30 | $3.06M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $6.12M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $9.18M 10-Q · filed 2019-05-07 |
| 2018-09-30 | $3.06M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $8.93M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $9.23M 10-Q · filed 2018-05-08 |
| 2017-09-30 | $3.10M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $6.20M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $9.29M 10-Q · filed 2017-05-09 |
| 2016-09-30 | $3.10M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $6.20M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $9.30M 10-Q · filed 2016-05-09 |
| 2015-09-30 | $2.88M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $5.75M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $8.75M 10-Q · filed 2015-05-11 |
| 2014-09-30 | $2.80M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $5.60M 10-Q · filed 2014-08-04 |
| 2014-03-31 | $8.40M 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |